Immuno(T)herapy for age‐related diseases

During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients sufferi...

Full description

Saved in:
Bibliographic Details
Published in:EMBO molecular medicine 2023-01, Vol.15 (1), p.e16301-n/a
Main Authors: Gabandé‐Rodríguez, Enrique, Pfeiffer, Matilda, Mittelbrunn, María
Format: Article
Language:English
Subjects:
Age
Aged
Aging
Alzheimer's disease
Antigens
Cancer
Cardiac function
Chimeric antigen receptors
Cytotoxicity
Experiments
Humans
Immune system
Immunotherapy
Immunotherapy, Adoptive
Lymphocytes
Lymphocytes T
Neoplasms - therapy
Receptors, Chimeric Antigen
Senescence
T-Lymphocytes
Thymus gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients suffering from oncological processes, especially those affected by hematological neoplasms. Recent evidence suggest that the use of immunotherapy could be extended to non‐oncological diseases and could be especially relevant for age‐associated disorders, opening exciting therapeutic options for a wide range of diseases of the elderly. Here we comment on the emergence of T‐cell‐based immunotherapies as feasible approaches that could revolutionize the future of GeroScience. In this Commentary, M. Mittelbrunn, E Gabandé‐Rodríguez and M. Pffeifer discuss T cell‐based immunotherapy for age‐related diseases.
ISSN:1757-4676
1757-4684
DOI:10.15252/emmm.202216301